Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy
Open Access
- 15 January 2017
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 23 (2) , 342-350
Abstract
Pediatric brain and extracranial solid tumors are a diverse group of malignancies that represent almost half of all pediatric cancers. Standard therapy includes various combinations of surgery, cytotoxic chemotherapy, and radiation, which can be very harmful to a developing child, and survivors carry a substantial burden of long-term morbidities. Although these therapies have improved survival rates for children with solid tumors, outcomes still remain extremely poor for subsets of patients. Recently, immunosuppressive checkpoint molecules that negatively regulate immune cell function have been described. When found on malignant cells or in the tumor microenvironment, they contribute to immune evasion and tumor escape. Agents designed to inhibit these proteins have demonstrated significant efficacy in human adult solid tumor studies. However, there is limited research focusing on immune checkpoint molecules and inhibitors in pediatric solid tumors. In this review, we examine the current knowledge on immune checkpoint proteins with an emphasis on cytotoxic T lymphocyte antigen-4 (CTLA-4); programmed cell death protein-1 (PD-1) and programmed death-ligand 1 (PD-L1); OX-2 membrane glycoprotein (CD200); and indoleamine 2,3-dioxygenase (IDO). We review T-cell signaling, the mechanisms of action of these checkpoint molecules, pediatric preclinical studies on checkpoint proteins and checkpoint blockade, pediatric checkpoint inhibitor clinical trials conducted to date, and future immunotherapy opportunities for childhood cancers. Clin Cancer Res; 23(2); 342–50. ©2016 AACR.Keywords
This publication has 76 references indexed in Scilit:
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced MelanomaJournal of Clinical Oncology, 2013
- T-Regulatory Cells: Key Players in Tumor Immune Escape and AngiogenesisCancer Research, 2012
- Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cellsLeukemia, 2012
- Indoleamine 2,3-Dioxygenase Tissue Distribution and Cellular Localization in Mice: Implications for Its Biological FunctionsJournal of Histochemistry & Cytochemistry, 2009
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodiesJournal of Experimental Medicine, 2009
- How regulatory T cells workNature Reviews Immunology, 2008
- B7-H1 Expression in Wilms Tumor: Correlation With Tumor Biology and Disease RecurrenceJournal of Urology, 2008
- Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and HypophysitisJournal of Immunotherapy, 2007
- Tissue expression of PD-L1 mediates peripheral T cell toleranceJournal of Experimental Medicine, 2006
- Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated l-tryptophan metabolismBiochemical and Biophysical Research Communications, 2005